Having trouble accessing articles? Reset your cache.

RotaTeq: Phase III data

In the Asian portion of a double-blind Phase III trial in 2,036 infants ages 4-12 weeks, RotaTeq was 48.3% effective in preventing severe rotavirus

Read the full 249 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE